Volume | 413,688 |
|
|||||
News | - | ||||||
Day High | 39.26 | Low High |
|||||
Day Low | 38.23 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Halozyme Therapeutics Incorporated | HALO | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
38.51 | 38.23 | 39.26 | 38.47 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
8,099 | 413,688 | $ 38.61 | $ 15,972,415 | - | 29.85 - 59.46 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
14:21:49 | 2 | $ 38.415 | USD |
Halozyme Therapeutics (HALO) Options Flow Summary
Halozyme Therapeutics Incorporated Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.07B | 131.92M | - | 660.12M | 202.13M | 1.53 | 25.06 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Halozyme Therapeutics News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical HALO Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 39.77 | 40.54 | 38.14 | 39.27 | 696,534 | -1.36 | -3.42% |
1 Month | 43.07 | 43.33 | 37.43 | 39.84 | 930,159 | -4.66 | -10.82% |
3 Months | 36.85 | 45.00 | 35.71 | 41.09 | 989,646 | 1.56 | 4.23% |
6 Months | 34.79 | 45.00 | 29.85 | 37.22 | 1,137,830 | 3.62 | 10.41% |
1 Year | 39.07 | 59.46 | 29.85 | 43.04 | 1,240,446 | -0.66 | -1.69% |
3 Years | 26.12 | 59.46 | 25.69 | 41.68 | 1,188,900 | 12.29 | 47.05% |
5 Years | 17.92 | 59.46 | 12.71 | 33.09 | 1,157,035 | 20.49 | 114.34% |
Halozyme Therapeutics Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally. |